Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapid Reversal of Suicidal Depression: Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

NCT06034821 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT06034821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06034821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapid Reversal of Suicidal Depression: Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
October 1, 2023
Completion date
December 1, 2030
Enrollment
1,500 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute suicidal depression (asd)